Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Bevacizumab + Chemotherapy (CT) is approved by the FDA and EMA for non-squamous NSCLC, including lung adenocarcinoma, as first-line treatment for unresectable advanced, recurrent, or metastatic disease.
The FDA approves bevacizumab with carboplatin and paclitaxel as first-line therapy for unresectable, metastatic, or recurrent nonsquamous NSCLC.
The FDA acknowledges the carboplatin/paclitaxel/bevacizumab regimen as a control arm in the I…